The Science Behind EsoBiotec
At EsoBiotec, we are revolutionizing cancer treatment by reprogramming immune cells directly inside the patient’s body.
Our proprietary ENaBL platform of 3rd generation, cell-specific, immune-shielded lentiviral vectors generation, cell specific, immune shielded lentiviral vectors is engineered to deliver superior safety, efficacy, and scalability, providing off-the-shelf solutions for patients battling cancer and autoimmune diseases.
Our pipeline
We are advancing a robust pipeline of innovative therapies designed to redefine cancer and autoimmune disease treatment. Powered by our ENaBL platform, our clinical programs focus on delivering cost-effective, off-the-shelf solutions that address significant unmet medical needs with scalability and precision.
What Sets ENaBL Apart?
- Immune-shielded lentiviral vectors ensure high precision and potency.
- Modular technology enables compatibility with a wide range of cell types and therapeutic applications.
- Scalable manufacturing delivers reliable, cost-effective treatments for global use.
Request Our Data
We believe in transparency and collaboration. For detailed scientific data supporting our platform’s efficacy and safety,
